details

Looking for Technical Partner of super long acting β-interferon

We are looking for a technical partner of β-interferon on behalf of a Korean Company who develops long-acting β-interferon for MS. The company’s long-acting β-interferon is designed to be injected on the basis of Four weeks while commercial long-acting β-interferon on market is injected on the basis of Two weeks. This long-acting β-interferon is currently at pre-clinic stage in the company. The company is now looking for a potential partner company who has intention to do the R&D work together and/or to ask for technology transfer.

Commercial β-interferon market is dominated by Biogen (US), Merck Serono (Germany), Bayer (Germany), and Novartis (Switzerland). The demand for long-acting β-interferon grows significantly to reduce injection frequency. Due to the longer acting period of the Four weeks-based β-interferon, we believe there is a huge market potential for this newly developed long-acting β-interferon when being commercialized.

If you are interested in this long-acting β-interferon and wish to learn more about it, please do not hesitate to contact us.